C21 Investments Inc.

CWLXF ·Healthcare, Drug Manufacturers - General
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-3.2M $-4.0M $-3.3M $293.2K $10.0M $-7.8M $-32.6M $-23.6M
Depreciation & Amortization $1.8M $1.7M $1.4M $1.8M $1.8M $2.3M — —
Depreciation $611.1K $585.1K $559.7K $533.7K $473.0K $630.8K $699.4K $383.1K
Amortization $1.7M $1.6M $1.3M $1.3M $1.4M $1.5M — $239.9K
Stock-Based Compensation $236.8K $849.6K $22.1K $209.4K $366.5K $494.4K $492.6K $3.0M
Net Cash from Operating Activities $1.4M $1.4M $3.3M $6.0M $8.4M $8.5M $5.5M $-11.4M
Investing Activities
Capital Expenditures $244.8K $406.7K $521.6K $442.3K $2.6M $227.8K $509.6K $208.1K
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities — — — — — $-1.1M $-4.5M $-18.7M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases $103.0K $276.7K $0 — — — — —
Net Cash from Financing Activities — — — — — $-5.7M $-7.1M $39.2M
Net Change in Cash $-391.2K $-635.1K $516.8K $-1.2M $-3.2M $3.2M $-6.0M $8.9M
Free Cash Flow $1.1M $958.9K $2.7M $5.5M $5.9M $8.3M $5.0M $-11.6M
← Newer Page 1 of 2 Older →